Posted 7th August 2017 by Jane Williams
At the dawn of the last century, people who were heralded as world-changers were a different breed. Edison, Franklin (and let’s also put Tesla here, though his contributions weren’t recognized at the time), Turing, Neumann, and a lot of other great people. Things are different now. The people we idolize today are the innovators – Jobs, Musk, Page&Brin – the Great Communicators who can drive products to the market, and carve out a viable market strategy despite the strong competition, or create entirely new markets.
Posted 17th July 2017 by Jane Williams
In recent times, we have seen advances in precision medicine lead to powerful discoveries and improved patient care. Liquid biopsies for example, now have the potential to be a real game-changer in cancer testing and could revolutionise cancer care.
Posted 7th June 2017 by Jane Williams
Unreasonable cost of trial-and-error medicine means precision medicine is imperative for targeted therapies
Rising pressures to decrease healthcare cost globally, the emergence of value-based reimbursement models and healthcare digitisation trends are transitioning the medication model from ‘one-size-fits-all’ to stratified and outcome based targeted therapies.
Posted 8th May 2017 by Jane Williams
Future of immunotherapies
Immunotherapies are on the fast growth trajectory which will be moderated based on responder groups, toxicity and efficacy results and high costs and increasingly used in combination therapies. The overall immune oncology checkpoint inhibitor market was over $2.0 billion and is set to grow to $14 billion by 2018.
Posted 17th February 2017 by Jane Williams
President Jimmy Carter announced last spring that he no longer needed treatments for the metastatic melanoma found in his brain – after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer.
Posted 11th November 2016 by Jane Williams
The genomic and post-genomic age promises much for clinical medicine, largely because we can now comprehensively sequence genomic DNA to identify polymorphisms, patterns and mutations. We can also measure gene expression routinely and systematically and with high sensitivity measure the amounts of proteins produced.